|
1
|
Naishadham D, Lansdorp-Vogelaar I, Siegel
R, Cokkinides V and Jemal A: State disparities in colorectal cancer
mortality patterns in the United States. Cancer Epidemiol
Biomarkers Prev. 20:1296–1302. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J clin.
61:69–90. 2011. View Article : Google Scholar
|
|
3
|
Center MM, Jemal A and Ward E:
International trends in colorectal cancer incidence rates. Cancer
Epidemiol Biomarkers Prev. 18:1688–1694. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ferrari P, Jenab M, Norat T, et al:
Lifetime and baseline alcohol intake and risk of colon and rectal
cancers in the European prospective investigation into cancer and
nutrition (EPIC). Int J Cancer. 121:2065–2072. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Adams J and Kauffman M: Development of the
proteasome inhibitor Velcade (Bortezomib). Cancer Invest.
22:304–311. 2004. View Article : Google Scholar
|
|
6
|
Goy A, Younes A, McLaughlin P, et al:
Phase II study of proteasome inhibitor bortezomib in relapsed or
refractory B-cell non-Hodgkin’s lymphoma. J Clin Oncol. 23:667–675.
2005.
|
|
7
|
O’Connor OA, Wright J, Moskowitz C, et al:
Phase II clinical experience with the novel proteasome inhibitor
Bortezomib in patients with indolent non-Hodgkin’s lymphoma and
mantle cell lymphoma. J Clin Oncol. 23:676–684. 2005.PubMed/NCBI
|
|
8
|
Orlowski RZ and Baldwin AS Jr: NF-kappaB
as a therapeutic target in cancer. Trends Mol Med. 8:385–389. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Orlowski RZ and Kuhn DJ: Proteasome
inhibitors in cancer therapy: lessons from the first decade. Clin
Cancer Res. 14:1649–1657. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Voorhees PM and Orlowski RZ: The
proteasome and proteasome inhibitors in cancer therapy. Annu Rev
Pharmacol Toxicol. 46:189–213. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
QI W, White MC, Choi W, Guo C, Dinney C,
McConkey DJ and Siefker-Radtke A: Inhibition of inducible heat
shock protein-70 (hsp72) enhances bortezomib-induced cell death in
human bladder cancer cells. PLoS One. 8:e695092013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Cagnetta A, Cea M, Calimeri T, et al:
Intracellular NAD+ depletion enhances bortezomib-induced
anti-myeloma activity. Blood. 122:1243–1255. 2013.
|
|
13
|
Tseng LM, Liu CY, Chan KC, Chu PY, Shiau
CW and Chen KF: CIP2A is a target of Bortezomib in human triple
negative breast cancer cells. Breast Cancer Res. 14:R682012.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Lin YC, Chen KC, Chen CC, Cheng AL and
Chen KF: CIP2A-mediated Akt activation plays a role in
bortezomib-induced apoptosis in head and neck squamous cell
carcinoma cells. Oral Oncol. 48:585–593. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Liu CY, Shiau CW, Kuo HY, Huang HP, Chen
MH, Tzeng CH and Chen KF: Cancerous inhibitor of protein
phosphatase 2A determines bortezomib-induced apoptosis in leukemia
cells. Haematologica. 98:729–738. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Chen KF, Liu CY, Lin YC, Yu HC, Liu TH,
Hou DR, Chen PJ and Cheng AL: CIP2A mediates effect of bortezomib
on phospho-Akt and apoptosis in hepatocellular carcinoma cells.
Oncogene. 29:6257–6266. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Junttila MR, Puustinen P, Niemelä M, et
al: CIP2A inhibits PP2A in human malignancies. Cell. 130:51–62.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Li W, Ge Z, Liu C, Björkholm M, Jia J and
Xu D: CIP2A is overexpressed in gastric cancer and its depletion
leads to impaired clonogenicity, senescence, or differentiation of
tumor cells. Clin Cancer Res. 14:3722–3728. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Böckelman C, Koskensalo S, Hagström J,
Lundin M, Ristimäki1 A and Haglund C: CIP2A overexpression is
associated with c-Myc expression in colorectal cancer. Cancer Biol
Ther. 13:289–295. 2012.PubMed/NCBI
|
|
20
|
Côme C, Laine A, Chanrion M, et al: CIP2A
is associated with human breast cancer aggressivity. Clin Cancer
Res. 15:5092–5100. 2009.PubMed/NCBI
|
|
21
|
Kulp SK, Yang YT, Hung CC, et al:
3-phosphoinositide-dependent protein kinase-1/Akt signaling
represents a major cyclooxygenase-2-independent target for
celecoxib in prostate cancer cells. Cancer Res. 64:1444–1451. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Chen KF, Yeh PY, Yeh KH, et al:
Down-regulation of phospho-Akt is a major molecular determinant of
bortezomib-induced apoptosis in hepatocellular carcinoma cells.
Cancer Res. 68:6698–6707. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Vaarala MH, Väisänen MR and Ristimäki A:
CIP2A expression is increased in prostate cancer. J Exp Clin Cancer
Res. 29:1362010. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Dong QZ, Wang Y, Dong XJ, Li ZX, Tang ZP,
Cui QZ and Wang EH: CIP2A is overexpressed in non-small cell lung
cancer and correlates with poor prognosis. Ann Surg Oncol.
18:857–865. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Coenen EA, Zwaan CM, Meyer C, et al:
KIAA1524: a novel MLL translocation partner in acute myeloid
leukemia. Leuk Res. 35:133–135. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Khanna A, Böckelman C, Hemmes A, et al:
MYC-dependent regulation and prognostic, role of CIP2A in gastric
cancer. J Natl Cancer Inst. 101:793–805. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Yi F, Ni W, Bai J and Li W: Expression and
biological role of CIP2A in human astrocytoma. Mol Med Rep.
7:1376–1380. 2013.PubMed/NCBI
|
|
28
|
Huang LP, Savoly D, Sidi AA, Adelson ME,
Mordechai E and Trama JP: CIP2A protein expression in high-grade,
high-stage bladder cancer. Cancer Med. 1:76–81. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Böckelman C, Lassus H, Hemmes A, et al:
Prognostic role of CIP2A expression in serous ovarian cancer. Br J
Cancer. 105:989–995. 2011.
|
|
30
|
Teng HW, Yang SH and Lin JK: CIP2A is a
predictor of poor prognosis in colon cancer. J Gastrointest Surg.
16:1037–1047. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Pitts TM, Morrow M, Kaufman SA, Tentler JJ
and Eckhardt SG: Vorinostat and bortezomib exert synergistic
antiproliferative and proapoptotic effects in colon cancer cell
models. Mol Cancer Ther. 8:342–349. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Choi YA, Park JS, Park MY, et al: Increase
in CIP2A expression is associated with doxorubicin resistance. FEBS
Lett. 585:755–760. 2011. View Article : Google Scholar : PubMed/NCBI
|
